Please enable JavaScript to continue using this application.

Compare $INMB vs $KLRS | Chartloom

Compare

$INMB vs $KLRS

INmune Bio Inc · Kalaris Therapeutics Inc

INMB

INmune Bio Inc

KLRS

Kalaris Therapeutics Inc

Compare $INMB vs $KLRS

Comparing INmune Bio Inc and Kalaris Therapeutics Inc

INMBINmune Bio Inc

KLRSKalaris Therapeutics Inc

INMBINmune Bio Inc

Market cap

$50M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

22.7%

52W performance

-6.0%

FCF yield

-31.3%

KLRSKalaris Therapeutics Inc

Market cap

$56M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.6%

52W performance

-64.2%

FCF yield

-73.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INMB

KLRS

Detailed metrics comparison

INMB

INmune Bio Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

INMB$50M

KLRS$56M

Enterprise Value

INMB$32M

KLRS$45M

Price

INMB$1.89

KLRS$2.36

P/E Ratio

INMBN/A

KLRSN/A

P/S Ratio

INMB1,071.30x

KLRS0.00x

EV/Sales

INMB703.08x

KLRS0.00x

EV/EBITDA

INMB0.00x

KLRS0.00x

P/B Ratio

INMB2.63x

KLRS1.02x

P/FCF Ratio

INMBN/A

KLRSN/A

EV/FCF

INMB-2.02x

KLRS-1.09x

PEG Ratio

INMBN/A

KLRSN/A

Forward P/E (NTM)

INMBN/A

KLRSN/A

Forward P/S (NTM)

INMBN/A

KLRSN/A

Revenue (TTM)

INMB$0

KLRS$0

Revenue Growth (YoY)

INMB-100.0%

KLRSN/A

Forward Rev Growth

INMB150.6%

KLRS180.3%

Gross Margin (TTM)

INMB0.0%

KLRS0.0%

Operating Margin (TTM)

INMB0.0%

KLRS0.0%

EBITDA Margin (TTM)

INMB0.0%

KLRS0.0%

Net Margin (TTM)

INMB0.0%

KLRS0.0%

FCF Margin (TTM)

INMBN/A

KLRSN/A

Net Income (TTM)

INMB$-18M

KLRS$-44M

FCF (TTM)

INMB$-16M

KLRS$-41M

EPS (TTM)

INMB-$0.69

KLRS-$1.86

ROE (TTM)

INMB-8287.0%

KLRS-7171.0%

ROA (TTM)

INMB-6223.0%

KLRS-4295.0%

ROIC (TTM)

INMB-8287.0%

KLRS-4719.0%

Cash

INMB$18M

KLRS$43M

Debt

INMB$0

KLRS$32M

Net Cash/Debt

INMB$18M

KLRS$11M

Current Ratio (TTM)

INMB4.04x

KLRS10.98x

Quick Ratio (TTM)

INMB3.94x

KLRS10.76x

Debt/Equity (TTM)

INMB0.00x

KLRS0.56x

Debt/Assets (TTM)

INMB0.0%

KLRS0.0%

Interest Coverage (TTM)

INMBN/A

KLRSN/A

Net Debt/EBITDA (TTM)

INMB0.00x

KLRS0.00x

Beta

INMB0.91

KLRS0.44

52W Performance

INMB-6.0%

KLRS-64.2%

YTD Performance

INMB22.7%

KLRS-71.6%

% from 52W High

INMB-27.3%

KLRS-80.1%

% from 52W Low

INMB73.4%

KLRS0.4%

Asset Turnover (TTM)

INMB0.00x

KLRS0.00x

FCF Yield (TTM)

INMB-31.3%

KLRS-73.4%

Earnings Yield (TTM)

INMB-36.6%

KLRS-78.8%

Dividend Yield (TTM)

INMBN/A

KLRSN/A

Rule of 40

INMB-100.0

KLRS0.0

EV/GP/RG

INMBN/A

KLRSN/A

Ticker research

View INMB research View KLRS research

Metric	INMB INmune Bio Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$50M	$56M
Enterprise Value	$32M	$45M
Price	$1.89	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	1,071.30x	0.00x
EV/Sales	703.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.63x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.02x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	150.6%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-18M	$-44M
FCF (TTM)	$-16M	$-41M
EPS (TTM)	-$0.69	-$1.86
ROE (TTM)	-8287.0%	-7171.0%
ROA (TTM)	-6223.0%	-4295.0%
ROIC (TTM)	-8287.0%	-4719.0%
Financial Health
Cash	$18M	$43M
Debt	$0	$32M
Net Cash/Debt	$18M	$11M
Current Ratio (TTM)	4.04x	10.98x
Quick Ratio (TTM)	3.94x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	0.44
52W Performance	-6.0%	-64.2%
YTD Performance	22.7%	-71.6%
% from 52W High	-27.3%	-80.1%
% from 52W Low	73.4%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-31.3%	-73.4%
Earnings Yield (TTM)	-36.6%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INMB research	View KLRS research

Valuation

P/S Ratio

KLRS

0.00x

INMB

1,071.30x

EV/FCF

INMB

-2.02x

KLRS

-1.09x

Growth & revenue

Revenue Growth TTM

INMB

-100.0%

Forward Revenue Growth

KLRS

180.3%

INMB

150.6%

Profitability & performance

Gross Margin

INMB

0.0%

KLRS

0.0%

ROE

KLRS

-7171.0%

INMB

-8287.0%

FCF Yield %

INMB

-31.3%

KLRS

-73.4%

52-Week Performance

INMB

-6.0%

KLRS

-64.2%

Detailed metrics comparison

INMB

INmune Bio Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

INMB$50M

KLRS$56M

Enterprise Value

INMB$32M

KLRS$45M

Price

INMB$1.89

KLRS$2.36

P/E Ratio

INMBN/A

KLRSN/A

P/S Ratio

INMB1,071.30x

KLRS0.00x

EV/Sales

INMB703.08x

KLRS0.00x

EV/EBITDA

INMB0.00x

KLRS0.00x

P/B Ratio

INMB2.63x

KLRS1.02x

P/FCF Ratio

INMBN/A

KLRSN/A

EV/FCF

INMB-2.02x

KLRS-1.09x

PEG Ratio

INMBN/A

KLRSN/A

Forward P/E (NTM)

INMBN/A

KLRSN/A

Forward P/S (NTM)

INMBN/A

KLRSN/A

Revenue (TTM)

INMB$0

KLRS$0

Revenue Growth (YoY)

INMB-100.0%

KLRSN/A

Forward Rev Growth

INMB150.6%

KLRS180.3%

Gross Margin (TTM)

INMB0.0%

KLRS0.0%

Operating Margin (TTM)

INMB0.0%

KLRS0.0%

EBITDA Margin (TTM)

INMB0.0%

KLRS0.0%

Net Margin (TTM)

INMB0.0%

KLRS0.0%

FCF Margin (TTM)

INMBN/A

KLRSN/A

Net Income (TTM)

INMB$-18M

KLRS$-44M

FCF (TTM)

INMB$-16M

KLRS$-41M

EPS (TTM)

INMB-$0.69

KLRS-$1.86

ROE (TTM)

INMB-8287.0%

KLRS-7171.0%

ROA (TTM)

INMB-6223.0%

KLRS-4295.0%

ROIC (TTM)

INMB-8287.0%

KLRS-4719.0%

Cash

INMB$18M

KLRS$43M

Debt

INMB$0

KLRS$32M

Net Cash/Debt

INMB$18M

KLRS$11M

Current Ratio (TTM)

INMB4.04x

KLRS10.98x

Quick Ratio (TTM)

INMB3.94x

KLRS10.76x

Debt/Equity (TTM)

INMB0.00x

KLRS0.56x

Debt/Assets (TTM)

INMB0.0%

KLRS0.0%

Interest Coverage (TTM)

INMBN/A

KLRSN/A

Net Debt/EBITDA (TTM)

INMB0.00x

KLRS0.00x

Beta

INMB0.91

KLRS0.44

52W Performance

INMB-6.0%

KLRS-64.2%

YTD Performance

INMB22.7%

KLRS-71.6%

% from 52W High

INMB-27.3%

KLRS-80.1%

% from 52W Low

INMB73.4%

KLRS0.4%

Asset Turnover (TTM)

INMB0.00x

KLRS0.00x

FCF Yield (TTM)

INMB-31.3%

KLRS-73.4%

Earnings Yield (TTM)

INMB-36.6%

KLRS-78.8%

Dividend Yield (TTM)

INMBN/A

KLRSN/A

Rule of 40

INMB-100.0

KLRS0.0

EV/GP/RG

INMBN/A

KLRSN/A

Ticker research

View INMB research View KLRS research

Metric	INMB INmune Bio Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$50M	$56M
Enterprise Value	$32M	$45M
Price	$1.89	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	1,071.30x	0.00x
EV/Sales	703.08x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.63x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.02x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	150.6%	180.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-18M	$-44M
FCF (TTM)	$-16M	$-41M
EPS (TTM)	-$0.69	-$1.86
ROE (TTM)	-8287.0%	-7171.0%
ROA (TTM)	-6223.0%	-4295.0%
ROIC (TTM)	-8287.0%	-4719.0%
Financial Health
Cash	$18M	$43M
Debt	$0	$32M
Net Cash/Debt	$18M	$11M
Current Ratio (TTM)	4.04x	10.98x
Quick Ratio (TTM)	3.94x	10.76x
Debt/Equity (TTM)	0.00x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	0.44
52W Performance	-6.0%	-64.2%
YTD Performance	22.7%	-71.6%
% from 52W High	-27.3%	-80.1%
% from 52W Low	73.4%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-31.3%	-73.4%
Earnings Yield (TTM)	-36.6%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INMB research	View KLRS research